Gd-dota Monoamide
Gd-dota Monoamide - Related Videos
03:36
Pretargeted Radioimmunotherapy: A Method for Targeted Delivery of Therapeutic Radionuclides to Tumors
0 Views •
2023
This video describes the technique of pretargeted radioimmunotherapy or PRIT, in which immunoconjugates followed by radioligands are administered for treating tumors. This radioimmunotherapy reduces radiation doses to healthy tissues and utilizes radionuclides with very low half-lives incompatible with antibody-based vectors.
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
0 Views •
Cited by 3 •
2013
To demonstrate MR cancer molecular imaging with a small peptide targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma in a mouse prostate cancer model.
FAQs
The gadolinium-bound water molecule and nearby water molecules exchange with the surrounding tissue environment. This exchange transfers the influence of the paramagnetic Gd3+ ion to tissue protons, accelerating longitudinal relaxation. The resulting change in T1 relaxation can increase signal on T1-weighted images, linking molecular water dynamics directly to contrast enhancement.
The DOTA-derived ligand controls how the Gd3+ ion is coordinated within the compound. That coordination environment is important because molecular structure affects both gadolinium retention and the agent’s interaction with water. Consequently, ligand design must balance the ability to produce useful relaxation effects with the stability needed for safer biological performance.
Optimization requires considering relaxivity, chelate stability, gadolinium retention, and biological performance together. Increasing MRI signal alone does not fully establish suitability, because the compound must also maintain an appropriate coordination structure and stable behavior in the biological environment. These relationships make molecular design central to evaluating whether an agent can provide effective and safer imaging.
Evaluation can relate the compound’s chelate structure to its relaxivity, gadolinium retention, and biological performance. MRI signal enhancement provides information about relaxation effects, while structural and retention considerations address how the agent behaves as a coordination compound. Examining these properties together gives a broader basis for judging contrast-agent design than image intensity by itself.
Research on Gd-DOTA monoamide can help clarify how changes in a gadolinium chelate influence MRI enhancement and safety-related behavior. This knowledge supports the design of contrast agents that are both effective and stable. In medical imaging development, such work connects molecular coordination chemistry with the practical goal of improving anatomical visualization.
By increasing signal on T1-weighted MRI through its effects on longitudinal proton relaxation, Gd-DOTA monoamide can support investigations of anatomical features and disease-related changes. Its research value extends beyond producing contrast, because comparing image enhancement with biological performance may help assess how agent design affects the interpretation of tissue imaging.